Share

October 2022; 12 (5) Research Article

Virtual Charcot-Marie-Tooth Examination Score

A Validated Virtual Evaluation for People With Charcot-Marie-Tooth Disease

Valeria Prada, Matilde Laurà, Riccardo Zuccarino, Mary M. Reilly, Michael E. Shy
First published August 31, 2022, DOI: https://doi.org/10.1212/CPJ.0000000000200070
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
45

Share

Article Information

vol. 12 no. 5 e98-e104
DOI: 
https://doi.org/10.1212/CPJ.0000000000200070
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • Received April 5, 2022
  • Accepted June 27, 2022
  • First Published August 31, 2022.

Article Versions

Copyright & Usage: 
© 2022 American Academy of Neurology

Author Disclosures

    1. Valeria Prada, PhD, PT,
    2. Matilde Laurà, MD, PhD,
    3. Riccardo Zuccarino, MD, PhD,
    4. Mary M. Reilly, MD and
    5. Michael E. Shy, MD
  1. Valeria Prada, PhD, PT,
    2. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Matilde Laurà, MD, PhD,
    3. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  3. Riccardo Zuccarino, MD, PhD,
    4. Scientific Advisory Boards:

    1. None

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  4. Mary M. Reilly, MD and
    5. Scientific Advisory Boards:

    1. Commercial<br><br>1. Eidos steering committee

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. (1) Neuromuscular Disorders, Editorial Board (current)<br>(2) European Journal of neurology, editorial board (current)

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1)Commercial entity:<br>Occasional consultancy for Alynam,<br>Inflectis, IONIS and Akcea

    Speakers' Bureaus:

    1. 1. Commercial Alnylam Symposium EAN 2021

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NIH grantS U54NS065712, 1UOINS109403-01, R21TR003034<br>MRC grant MR/S005021/1

    Research Support, Academic Entities:

    1. &#x0095;MDA grant (MDA510281) Muscle MRI in Charcot Marie <br>Tooth disease (PI) 2017-2021<br>CMTA grants for CMT1B,2A and 1X

    Research Support, Foundations and Societies:

    1. None

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  5. Michael E. Shy, MD
    6. Scientific Advisory Boards:

    1. (1) Charcot Marie Tooth Association-Non Profit<br>(2) Muscular Dystrophy Association (MDA)-Non Profit

    Gifts:

    1. Applied Therapeutics Commercial entity for developing a <br>treatment trial for a peripheral neuropathy. Not relevant to <br>the current study

    Funding for Travel or Speaker Honoraria:

    1. None

    Editorial Boards:

    1. Neuromuscular Disorders, Editorial Board<br>Muscle and Nerve, Editorial Board

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. (1) Alnylam Pharmaceuticals - Consultant<br>(2) Mitochondria in Motion-Consultant<br>(3) Inflectis BioSci - Consultant<br>(4) Neurogene - Consultant<br>(5) Applied Therapeutics - (Consultant)

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NINDS/Office of Rare Disease/NCATS

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. (1) Muscular Dystrophy Association;<br>(2) Charcot Marie Tooth Association

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. From the University of Iowa (V.P., M.E.S.), Carver College of Medicine, Iowa City, IA; FISM (V.P.), Fondazione italiana Sclerosi Multipla, Genova, Italy; Department of Neuromuscular Diseases (M.L., M.M.R.), UCL Queen Square Institute of Neurology and National Hospital for Neurology and Neurosurgery, London, United Kingdom; and Centro Clinico NeMO Trento (R.Z.), Fondazione Serena ONLUS, Pergine Valsugana (Trento), Italy.
  1. Correspondence
    Dr. Prada valeria.prada{at}gmail.com
View Full Text

Article usage

Article usage: August 2022 to December 2022

AbstractFullPdfSource
Aug 20229005Highwire
Sep 202220108Highwire
Oct 20223743723Highwire
Nov 2022284186Highwire
Dec 202215853Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me